Damora Therapeutics annual return on equity
2020
2021
2022
2023
2024
2025
Damora Therapeutics Return on Equity (ROE) Growth & History (DMRA)
Damora Therapeutics's return on equity was −163.80% for fiscal 2025.
View full Damora Therapeutics company overviewDamora Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −163.80% | −74.77 pp |
| 2024 | 2024-12-31 | −89.03% | −7.51 pp |
| 2023 | 2023-12-31 | −81.52% | −12.66 pp |
| 2022 | 2022-12-31 | −68.86% | −32.25 pp |
| 2021 | 2021-12-31 | −36.61% | +37.24 pp |
| 2020 | 2020-12-31 | −73.85% | — |
Damora Therapeutics quarterly return on equity
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −6.07% | +21.81 pp |
| Q1 2026 | 2026-03-31 | −7.39% | +9.76 pp |
| Q4 2025 | 2025-12-31 | −161.63% | −124.96 pp |
| Q3 2025 | 2025-09-30 | −33.05% | −15.61 pp |
| Q2 2025 | 2025-06-30 | −27.87% | −7.24 pp |
| Q1 2025 | 2025-03-31 | −17.15% | +0.96 pp |
| Q4 2024 | 2024-12-31 | −36.67% | −18.09 pp |
| Q3 2024 | 2024-09-30 | −17.44% | +2.63 pp |
| Q2 2024 | 2024-06-30 | −20.63% | +2.22 pp |
| Q1 2024 | 2024-03-31 | −18.11% | +5.08 pp |
| Q4 2023 | 2023-12-31 | −18.58% | +2.35 pp |
| Q3 2023 | 2023-09-30 | −20.07% | −2.67 pp |
| Q2 2023 | 2023-06-30 | −22.85% | −4.73 pp |
| Q1 2023 | 2023-03-31 | −23.19% | −7.68 pp |
| Q4 2022 | 2022-12-31 | −20.92% | −10.06 pp |
| Q3 2022 | 2022-09-30 | −17.40% | −8.03 pp |
| Q2 2022 | 2022-06-30 | −18.12% | −9.75 pp |
| Q1 2022 | 2022-03-31 | −15.50% | −7.11 pp |
| Q4 2021 | 2021-12-31 | −10.86% | +20.53 pp |
| Q3 2021 | 2021-09-30 | −9.37% | — |
| Q2 2021 | 2021-06-30 | −8.37% | — |
| Q1 2021 | 2021-03-31 | −8.39% | — |
| Q4 2020 | 2020-12-31 | −31.39% | — |
Damora Therapeutics return on equity trends
Over the last five fiscal years, Damora Therapeutics's return on equity decreased from −73.85% to −163.80%, a change of −89.95 percentage points. The latest reported quarter, Q2 2026, shows −6.07%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Damora Therapeutics source filings ↗